智通财经6月17日电，香港交易所信息显示，LAV Asset Management (Hong Kong) Limited在信达生物的 持股比例于06月12日从5.00%降至3.09%。 ...

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical and biotech industry, indicating a positive outlook on their growth potential and market performance [6]. Core Insights - The ASCO conference showcased significant advancements in domestic innovative drugs, highlighting the competitive edge of Chinese pharmaceutical companies in the global market [4][12]. - The report emphasizes the clinical value and market potential of several key drugs presented at ASCO, including promising results from various companies [4][12]. Summary by Relevant Sections Domestic Key Research Overview - BaiLi Tianheng's BL-B01D1 demonstrated a 35.3% confirmed overall response rate (cORR) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) [18]. - DiZhe Pharmaceutical's DZD6008 achieved over 80% overall response rate (ORR) in heavily treated chronic lymphocytic leukemia (CLL) patients, indicating its potential as a new treatment option [4][12]. - FuHong HanLin's PD-L1 ADC showed excellent performance in immune-resistant squamous NSCLC patients, while HLX22 is expected to redefine first-line treatment for advanced gastric cancer [4][12]. - KeLun BoTai's sac-TMT data confirmed long-term survival benefits in third-line EGFR-mutant NSCLC and first-line triple-negative breast cancer (TNBC) [4][12]. - KangNing JieRui's HER2 bispecific ADC demonstrated comparable efficacy and better safety than existing treatments [4][12]. - MaiWei Biotech's 9MW2821 combined with toripalimab is anticipated to be a strong contender in first-line urothelial carcinoma treatment [4][12]. - SanSheng Pharmaceutical updated data on SSGJ-707 for first-line treatment of wild-type NSCLC, with a significant partnership with Pfizer [4][12]. - XinDa Biotech's IBI363 showed potential in activating "cold" tumors, aiming to become a cornerstone drug in immunotherapy [4][12]. - YaSheng Pharmaceutical's Lisaftoclax achieved positive results in patients resistant to venetoclax, filling a treatment gap in myeloid malignancies [4][12]. - ZhengDa TianQing's "DeFu combination" was selected for LBA, potentially offering a new first-line treatment for PD-L1 positive NSCLC [4][12]. - ZeJing Pharmaceutical and ZaiDing Pharmaceutical presented excellent data on ZG006 and ZL-1310 for late-line SCLC treatment, showcasing the global competitiveness of domestic drugs [4][12].

Summary of the Conference Call for Innovent Biologics Company Overview - **Company**: Innovent Biologics - **Industry**: Innovative Pharmaceuticals Key Points and Arguments Industry Dynamics - The innovative drug sector is experiencing a rebound driven by changes in demand and policy, with Hong Kong's innovative drug sector valuations rising, albeit limited by profit growth [2][3] - The sector is at a historical low valuation, with recent data from the ASCO conference showcasing the global competitiveness of domestic innovative drug companies [3] Financial Performance - Innovent Biologics reported strong revenue performance, with projected revenue exceeding 8.2 billion yuan in 2024, representing a 40% year-on-year growth [2][6] - Q4 product revenue is expected to surpass 2 billion yuan, showing a 25% increase year-on-year [2][6] Product Pipeline and Commercialization - The company anticipates commercializing 14 products within the next one to two years, with several entering NDA and NMPA reviews or critical clinical studies [2][7] - Expected new revenue streams from products like IGF-1R and peptide I23P19 are projected to help achieve EBITDA breakeven by 2025, with domestic product revenue reaching 20 billion yuan by 2027 [2][7] Key Products and Innovations - The PD-1/IL-2 fusion protein IBI363 has shown significant efficacy in treating IO-resistant non-small cell lung cancer and third-line colorectal cancer, with global peak sales potential estimated at 10 billion USD [2][9][10] - The drug's design enhances efficacy while reducing toxicity, showing promising data in clinical trials [9][10] Market Opportunities - The GIP/GLP-1 dual receptor agonist, Masitide, is expected to be approved by 2025, providing a new growth avenue for the company [4][12] - Innovent's comprehensive layout in the metabolic field, including the P9 monoclonal antibody, is expected to drive sales growth [4][13] Competitive Landscape - The company is well-positioned in the autoimmune sector with innovative drugs like IL-23 P19, which is anticipated to gain market approval soon [4][16] - The market for thyroid eye disease is significant, with approximately 4 million patients in China, and Innovent's IGF-1R antibody showing promising results [14] Valuation and Future Outlook - Innovent's projected revenue of 20 billion yuan by 2027 is seen as a target, with potential peak sales reaching 30 billion yuan based on ongoing clinical developments [8] - The company is suitable for DCF valuation rather than PS, as its early-stage assets have not been fully assessed [8] - The future outlook remains optimistic, with numerous catalysts expected from clinical data releases in the coming years [18] Conclusion - Innovent Biologics is positioned as a strong candidate for medium to long-term investment, supported by robust revenue growth, a promising product pipeline, and favorable market dynamics [18]

Market Overview - On June 16, the Hang Seng Index rose by 0.70%, closing at 24,060.99 points, with a total net inflow of HKD 57.43 billion through the southbound trading channel [1][3] - The total trading volume for the southbound trading was HKD 1,278.17 billion, with a net buy of HKD 57.43 billion [1] Trading Activity - The Shanghai Stock Exchange's southbound trading had a total transaction amount of HKD 779.26 billion, with a net buy of HKD 26.68 billion, while the Shenzhen Stock Exchange had a transaction amount of HKD 498.91 billion and a net buy of HKD 30.75 billion [1] - In the top ten active stocks on the Shanghai Stock Exchange, Xiaomi Group-W had the highest transaction amount of HKD 43.93 billion, followed by Shandong Molong and Alibaba-W with transaction amounts of HKD 40.27 billion and HKD 29.26 billion, respectively [1] Stock Performance - In terms of net buy amounts, China Construction Bank led with a net buy of HKD 11.08 billion, closing with a price increase of 1.97% [1] - Xiaomi Group-W recorded the highest net sell amount of HKD 14.89 billion, while its closing price increased by 4.23% [1] - In the Shenzhen Stock Exchange's top active stocks, Xiaomi Group-W again led with a transaction amount of HKD 34.12 billion, followed by Pop Mart and Meituan-W with transaction amounts of HKD 15.52 billion and HKD 15.46 billion, respectively [2] - Meituan-W had the highest net buy amount of HKD 6.22 billion, closing with a price increase of 0.43%, while Xiaomi Group-W had a net sell of HKD 3.91 billion [2]

Core Insights - On June 16, 2025, Xiaomi Group-W (01810), Shandong Molong (00568), and Alibaba Group-W (09988) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 4.393 billion, 4.027 billion, and 2.926 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Xiaomi Group-W (01810), Pop Mart (09992), and Meituan-W (03690) led the trading volume, with amounts of 3.412 billion, 1.552 billion, and 1.546 billion respectively [1] Southbound Stock Connect (Shanghai-Hong Kong) - Top active companies by trading amount: - Xiaomi Group-W (01810): 4.393 billion, net buy of -1.489 billion - Shandong Molong (00568): 4.027 billion, net buy of 55.0174 million - Alibaba Group-W (09988): 2.926 billion, net buy of 311 million - Pop Mart (09992): 2.646 billion, net buy of 154 million - China Construction Bank (00939): 1.938 billion, net buy of 1.108 billion - Meituan-W (03690): 1.829 billion, net buy of 493 million - Tencent Holdings (00700): 1.802 billion, net buy of -322 million - ZhongAn Online (06060): 1.700 billion, net buy of 215 million - CNOOC (00883): 1.383 billion, net buy of -261 million - Yika (09923): 1.087 billion, net buy of -2.1563 million [2] Southbound Stock Connect (Shenzhen-Hong Kong) - Top active companies by trading amount: - Xiaomi Group-W (01810): 3.412 billion, net buy of -391 million - Pop Mart (09992): 1.552 billion, net buy of -83.2303 million - Meituan-W (03690): 1.546 billion, net buy of 622 million - Alibaba Group-W (09988): 1.457 billion, net buy of -284 million - Tencent Holdings (00700): 1.314 billion, net buy of -298 million - Shandong Molong (00568): 1.162 billion, net buy of 18.7368 million - Innovent Biologics (01801): 1.111 billion, net buy of -285 million - BeiGene (06160): 1.039 billion, net buy of -228 million - Kuaishou-W (01024): 987 million, net buy of -27.6221 million - CanSino Biologics (09926): 904 million, net buy of 20.6 million [2]

Core Insights - The pharmaceutical-themed funds are dominating the performance rankings for the first half of the year, with nine out of the top ten funds being pharmaceutical-focused, led by Huatai-PineBridge Hong Kong Advantage Select A, which achieved a 103.67% return [1][2] - The strong performance of these funds is driven by multiple factors, including breakthroughs in innovative drug development, recovery of liquidity in the Hong Kong stock market, and restructuring of valuation systems through cross-border business development transactions [1][2] Fund Performance - The average return of the top ten actively managed equity funds exceeds 69%, with notable performances from Changcheng Pharmaceutical Industry Select A and Yongying Pharmaceutical Innovation Smart Select A, achieving returns of 87.73% and 79.79% respectively [2] - Huatai-PineBridge Hong Kong Advantage Select A is highlighted as a "doubling fund" for the year, marking a significant achievement in the market [2] Market Dynamics - The pharmaceutical sector is experiencing a "double hit" in profitability and valuation in 2025, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index showing a year-to-date increase of 70.09% [3] - The performance of pharmaceutical funds is significantly influenced by their exposure to Hong Kong stocks, with the Hang Seng Healthcare Index rising by 54.59%, outperforming the A-share innovative drug index, which increased by 24.15% [3] Investment Strategy - Huatai-PineBridge Hong Kong Advantage Select A has benefited from investments in leading companies in the Hong Kong innovative drug and medical device sectors, capitalizing on improved overseas liquidity and favorable industry policies [4] - The introduction of financing channels for unprofitable biotech companies in Hong Kong has allowed competitive biotech firms to enter the market, with many now in advanced stages of research and commercialization [4] Future Outlook - The pharmaceutical industry is expected to maintain long-term investment value driven by demographic aging, consumption upgrades, and technological innovation, although caution is advised regarding potential overvaluation of certain stocks [6] - The current market for innovative drugs is characterized by high valuations and volatility, with expectations for a rebalancing between these factors in the near future [6][7] - The valuation of leading companies and key stocks is anticipated to be reassessed, with a focus on the long-term potential of authorized products and revenue realization from commercial partnerships [7]

Investment Rating - The report assigns an "Overweight" (OW) rating to Innovent, Akeso, and Kelun Biotech, indicating an expectation that these stocks will outperform the average total return of their coverage universe [4][7]. Core Insights - Innovent has shown strong investor interest, with a recent stock increase of approximately 3% following a share sale by Lilly Asia Ventures. The company achieved its first-ever non-IFRS positive profit and EBITDA in 2024, and this trend is expected to continue into 2025 and beyond. Innovent is anticipated to secure an outlicensing deal for IBI363, which holds significant value in the immuno-oncology therapy space [4]. - Akeso's share price rose by 10% on June 10, attributed to comments from its U.S. partner, Summit, regarding avoiding a cash raise and manufacturing Ivonescimab in-house. Summit plans to recruit participants for global trials from multiple regions, including China, the U.S., and the EU. The BLA filing strategy for HARMONi is still under discussion [4]. - Kelun Biotech completed an equity raise and does not require additional cash due to solid reserves. Promising ASCO data for Sac-TMT in treating triple-negative breast cancer and non-squamous non-small cell lung cancer indicates a higher probability of success in Phase 3 trials. The domestic Phase 3 trial is enrolling patients rapidly, with potential for an interim analysis this year [4][5]. Summary by Company Innovent - Innovent's stock increased by ~3% after a secondary share placement by Lilly Asia Ventures, which still holds a ~2% stake. The company achieved its first non-IFRS positive profit and EBITDA in 2024, with expectations for continued growth in 2025. Anticipated catalysts include an outlicensing deal for IBI363 [4][5]. Akeso - Akeso's share price increased by 10% following positive comments from Summit, its U.S. partner. Summit is working on in-house manufacturing of Ivonescimab and plans to recruit trial participants from various regions. The BLA filing strategy for HARMONi is still being evaluated [4][5]. Kelun Biotech - Kelun Biotech completed an equity raise and has solid cash reserves. Promising data for Sac-TMT in treating specific cancers suggests a high probability of success in upcoming trials. The company is rapidly enrolling patients for a domestic Phase 3 trial, with potential for an interim analysis this year [4][5].

Summary of Key Points from the Conference Call Industry Overview - The Chinese innovative drug industry is experiencing a systematic valuation increase, primarily benefiting from the realization of business development (BD) opportunities abroad, with multinational corporations (MNCs) beginning to pay for early pipeline products, reshaping the valuation system and reversing the previous reliance on domestic market payments [1][5][6]. Core Insights and Arguments - The industry has reached an operational turning point, with large biotech companies like BeiGene demonstrating profitability trends, entering a profit window, validating the market acceptance of the innovative drug commercialization model [1][5][6]. - MNCs are facing a patent cliff and urgently need to introduce innovative drugs through BD to fill sales gaps, while Chinese innovative drug research has made significant progress over the past decade, providing high-quality alternative products for BD collaborations [1][7]. - BD activities in the Chinese innovative drug sector are concentrated in the areas of antibody-drug conjugates (ADC) and second-generation immuno-oncology (IO), with companies like Kelun-Biotech and Innovent Biologics leading globally by enhancing product efficacy and reducing toxicity through innovative designs [1][9][10]. - The Harmony Two study data from CanSino Biologics has sparked MNC interest in the second-generation IO track, accelerating related layouts and facilitating several large BD transactions, such as BMS's collaboration with a biotech firm totaling over $9 billion [1][12]. Market Trends - The current innovative drug market is performing strongly, with minor adjustments observed primarily in second- and third-tier stocks, while core assets remain largely unaffected, indicating a good entry opportunity [2]. - The valuation levels of innovative drugs are not yet at a bubble stage, and the current market cycle is believed to be far from over, with a shift in valuation dynamics due to MNCs beginning to pay for early-stage products [3][5]. Future Prospects - The Chinese innovative drug industry is optimistic about future development, with more biotech companies entering profitability windows, further driving industry growth [6]. - The second-generation IO track is still in the expansion phase, with significant potential and investment prospects, particularly for companies like 3SBio, Innovent Biologics, and Abogen Biosciences [4][13]. Noteworthy Developments - The increase in BD activities is attributed to both supply and demand factors, with MNCs needing to fill sales gaps due to expiring patents on major drugs, while Chinese companies have made substantial advancements in drug development [7][8]. - The ADC and second-generation IO fields are highlighted as key areas of focus, with Chinese companies showing strong competitive advantages and technological capabilities [9][10]. Investment Logic and Company Classification - Investment logic varies among innovative drug companies based on their R&D direction, technology platform, and market demand, necessitating a comprehensive evaluation of specific fields and company strengths [16]. - Companies can be classified into four categories: early-stage biotech, pre-balance biotech, platform biopharma, and generic innovators, each with distinct characteristics and development stages [17][18]. Conclusion - The innovative drug sector in China is poised for growth, driven by advancements in BD activities, strong company performances, and a favorable market environment, making it a critical area for investment and research [1][6][19].

随着上半年公募基金业绩收官战进入倒计时，医药主题基金以碾压性优势席卷收益榜单。 Wind数据显示，截至6月14日，公募主动权益类基金前十名中竟有9只医药主题产品，汇添富香港优势精选A更 以103.67%的收益率率先撞线"翻倍基"，暂居收益率榜首，2025年半程 悬念花落谁家 ，值得期待。 多位公募业内人士对券商中国记者表示，这场由创新药研发突破、港股流动性复苏、跨境BD交易重构估值体 系等多重动能驱动的医药盛宴，不仅改写了年度基金排名格局，更折射出资本市场对"中国创新"力量的重估与 期待。 医药基金霸屏公募半年业绩榜 随着6月过半，半年度公募主动权益基金的业绩排名即将出炉。年初至今，医药板块延续强势表现，多只医药 主题基金凭借精准布局和行业红利实现业绩爆发，市场无重大变化之下，医药基金将成为半年度收益最大的赢 家。 以汇添富香港优势精选A为例，此前披露的一季报显示，一季度末前十大重仓股分别是荣昌生物、科伦博泰生 物-B、信达生物、和黄医药、康诺亚-B、翰森制药、康方生物、诺诚健华、来凯医药-B、百济神州，创新药概 念股占据绝大多数。 唐晨对记者表示，香港联交所于2018年推出18A上市规则，较科创板更早地为未 ...

Core Viewpoint - The Hong Kong stock market for innovative pharmaceuticals is experiencing a resurgence, with significant increases in stock prices and a record number of companies filing for IPOs, indicating a potential value reassessment after a prolonged downturn [2][4][12]. Group 1: Market Activity - As of mid-June, 18 innovative pharmaceutical companies have submitted applications to list on the Hong Kong Stock Exchange, with 7 of these occurring in just the first half of June, setting a historical record [1][3]. - The Hang Seng Innovative Pharmaceutical Index has rebounded to 51% of its historical high from July 2021, reflecting a recovery in market sentiment [5][12]. - Over 80% of the 18 newly listed pharmaceutical companies in Hong Kong have seen their stock prices rise since the beginning of 2025 [12]. Group 2: Investment Trends - The market is witnessing a shift in investor sentiment, with many previously cautious investors now eager to engage in the sector, driven by increased capital flow and favorable policy changes [4][16]. - The trend of License-out transactions has gained momentum, with the first quarter of 2025 seeing 41 such deals totaling $36.93 billion, indicating a significant increase in market activity compared to previous years [19][20]. - The proportion of mainland Chinese capital invested in the Hang Seng Innovative Pharmaceutical Index has risen from 18% at the beginning of the year to 22.6% [31]. Group 3: Company Performance - Notable companies like 3SBio and Innovent Biologics have seen their market capitalizations soar, with 3SBio's value tripling to over HKD 50 billion and Innovent's market cap exceeding HKD 100 billion [2][12]. - New listings are performing well, with companies like InnoCare Pharma seeing significant gains on their debut, indicating a shift in market dynamics [13]. Group 4: Future Outlook - The industry is optimistic about the future, with discussions among company founders shifting from survival strategies to expansion and acquisition plans [11][16]. - However, there are concerns about the sustainability of this growth, as the reliance on License-out deals may not provide a long-term solution without systemic support from the healthcare payment system [34][36].